Glenmark Pharmaceuticals gets US FDA approval for inhalation drug

Glenmark Pharmaceuticals Limited gained attention after its subsidiary received US Food and Drug Administration approval for fluticasone propionate inhalation aerosol. The drug targets a $520 million respiratory market and qualifies for 180-day competitive generic therapy exclusivity. The product will launch in March 2026 in the US.